LFA
VRTX icon

LGT Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

LGT Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$1.79K – 261
2026
Q1 		$1.79K Hold
4
– – 0.01% 232
2025
Q4 		$1.81K Hold
4
– – 0.01% 237
2025
Q3 		$1.57K Hold
4
– – ﹤0.01% 345
2025
Q2 		$1.78K Buy
+4
New +$1.84K ﹤0.01% 364
2024
Q3 		– Sell
-38
Closed -$17.8K – 793
2024
Q2 		$17.8K Buy
+38
New +$16.5K 0.04% 328
2024
Q1 		– Sell
-16
Closed -$6.51K – 864
2023
Q4 		$6.51K Hold
16
– – 0.01% 568
2023
Q3 		$5.56K Buy
+16
New +$5.6K 0.01% 590

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LGT Financial Advisors's VRTX Position: Q2 2026 in Review

LGT Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 4 shares — an estimated $1.79K sold.

LGT Financial Advisors first reported a position in VRTX in Q3 2023 and held it in 7 quarters. The position peaked at $17.8K in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LGT Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • LGT Financial Advisors sold 4 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.79K.
  • LGT Financial Advisors first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 7 quarters.
  • LGT Financial Advisors's Vertex Pharmaceuticals position peaked at $17.8K in Q2 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LGT Financial Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.